Cat. No.: HY-N0346

4-Methoxycinnamic acid ethyl ester

(Synonyms: Ethyl p-methoxycinnamate)

Customer Review

Based on 1 Customer Validation

4-Methoxycinnamic acid ethyl ester (Ethyl p-methoxycinnamate) is an orally active natural compound found. 4-Methoxycinnamic acid ethyl ester exerts anti-inflammatory effects by inhibiting cyclooxygenase (COX-1 (IC₅₀ = 1.12 μM) and COX-2 (IC₅₀ = 0.83 μM)), NF-κB (IC₅₀ = 88.7 μM) and cytokine production (TNF-α (IC₅₀ = 96.84 μg/mL) and IL-1β (IC₅₀ = 166.4 μg/mL)). 4-Methoxycinnamic acid ethyl ester inhibits tumor cell proliferation, migration and cancer metabolism and induces apoptosis.4-Methoxycinnamic acid ethyl ester inhibits VEGF expression, thereby inhibiting angiogenesis. 4-Methoxycinnamic acid ethyl ester has a significant inhibitory effect on dengue virus and Mycobacterium tuberculosis. 4-Methoxycinnamic acid ethyl ester has analgesic effects in rats.

For research use only. We do not sell to patients.

Purity: 98.72%
CAS No.: 1929-30-2
Formula: C₁₂H₁₄O₃
Molecular Weight:206.24

Storage:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

4-Methoxycinnamic acid ethyl ester Chemical Structure

CAS No.: 1929-30-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]^[2]^[7]

COX-1

1.12 μM (IC₅₀)

COX-2

0.83 μM (IC₅₀)

NF-κB

88.7 μM (IC₅₀)

IL-1β

116.4 μg/mL (IC₅₀)

Caspase-3

Caspase-7

Caspase-8

Caspase-9

All COX Isoforms :

All NF-κB Isoforms :

All TNF Receptor Isoforms :

All Interleukin Related Isoforms :

All VEGFR Isoforms :

All Caspase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	31.29 μM Compound: 6	Cytotoxicity against human A375 cells by MTT assay Cytotoxicity against human A375 cells by MTT assay	[PMID: 19782567]
HL-60	IC₅₀	29.64 μM Compound: 6	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 19782567]
THP-1	IC₅₀	33.52 μM Compound: 6	Cytotoxicity against human THP1 cells by MTT assay Cytotoxicity against human THP1 cells by MTT assay	[PMID: 19782567]

In Vitro

4-Methoxycinnamic acid ethyl ester (25-200 μg/mL, 0-48 h) inhibits the growth of HUVECs with an IC₅₀ of 160 μg/mL and suppresses the migration ability of HUVECs through VEGF^[2].
4-Methoxycinnamic acid ethyl ester (50-200 μg/mL, 6-24 h) dose-dependently impairs the ability of HUVECs to form tube-like structures on Matrigel^[2].
4-Methoxycinnamic acid ethyl ester (50-200 μg/mL, 5 d) significantly inhibits the sprouting and growth of microvessels from rat aortic rings^[2].
4-Methoxycinnamic acid ethyl ester (0.03-0.97 mM, 7 d) inhibits M. tuberculosis H37Ra, H37Rv, drug susceptible and multidrug resistant (MDR) clinical isolates (MIC: 0.242-0.485 mM) and is ineffective against common bacteria such as Mycobacterium smegmatis, Escherichia coli, and Staphylococcus aureus^[3].
4-Methoxycinnamic acid ethyl ester (50 μM, 12 h) significantly reduces the phosphorylation levels of p-p65 (Ser536) and p-Akt (Ser473) in melanoma cells^[4].
4-Methoxycinnamic acid ethyl ester (50 μM, 24 h) significantly inhibits the migration and invasion ability of melanoma cells^[4].
4-Methoxycinnamic acid ethyl ester (1-50 μM, 12-24 h) reverses the resistance of melanoma cells to Paclitaxel (HY-B0015)^[4].
4-Methoxycinnamic acid ethyl ester (125-500 μM, 24 h) exhibits broad-spectrum antiviral activity against all four dengue serotypes (DENV-1, DENV-2, DENV-3, DENV-4), with EC₅₀ values of 22.58 and 6.17 μM for DENV-2 in HepG2 and A549 cells, respectively^[5].
4-Methoxycinnamic acid ethyl ester (100 μM, 1-24 h) inhibits de novo fatty acid synthesis, rather than glycolysis, to deplete ATP in ehrlich ascites cancer cells (EATCs)^[6].
4-Methoxycinnamic acid ethyl ester (48 h) shows moderate cytotoxicity against MCF-7, HT-29, HCT-116 (IC₅₀ = 42.1 μg/mL), U-937, PC-3 (IC₅₀ = 39 μg/mL), K-562 cells^[7].
4-Methoxycinnamic acid ethyl ester (50-200 μg/mL, 12-48 h) inhibits cell migration and induces apoptosis via the mitochondrial pathway in HCT-116 cells^[7].
4-Methoxycinnamic acid ethyl ester (200 μg/mL, 8 h) significantly activates all tested caspases, including Caspase-9, Caspase-8, and Caspase-3/7 in HCT-116 cells^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay ^[2]

Cell Line:

HUVECs
Concentration:

50, 100, 200 μg/mL
Incubation Time:

0, 6 and 12 h
Result:

Effectively prevented the migration of endothelial cells to the damaged area.

Western Blot Analysis^[4]

Cell Line:

B16F10 G5-Luc and SK-Mel 28
Concentration:

50 μM
Incubation Time:

12 h (B16F10 G5-Luc) and 24 h (SK-Mel 28)
Result:

Significantly reduced the phosphorylation levels of p-p65 (Ser536) and p-Akt (Ser473).
Upregulated the expression of γ-H2AX with Paclitaxel.

Cell Migration Assay ^[4]

Cell Line:

B16F10 G5-Luc
Concentration:

50 μM
Incubation Time:

12 h
Result:

Significantly inhibited the migration.

Cell Invasion Assay^[4]

Cell Line:

B16F10 G5-Luc
Concentration:

50 μM
Incubation Time:

12 h
Result:

Significantly reduced the number of cells passing through Matrigel.

Western Blot Analysis^[4]

Cell Line:

143B cells
Concentration:

2.5 μM
Incubation Time:

1, 2, 4, 8, 16 and 24 h
Result:

Activated caspases and increased PARP-1 cleavage.
Promoted the phosphorylation of p53, and upregulated PUMA and Bax.
Increased the level of γH2AX.

RT-PCR^[6]

Cell Line:

EATCs
Concentration:

100 μM
Incubation Time:

1, 6 and 12 h
Result:

Significantly downregulated the mRNA expression of key enzymes in fatty acid synthesis, including Acly, Acc1, and Fasn.
Was no significant effect on the mRNA expression of key fatty acid oxidation enzymes Cpt1a and Cpt1b.
Significantly downregulated the expression levels of SREBP1 mRNA.

Western Blot Analysis^[6]

Cell Line:

EATCs
Concentration:

100 μM
Incubation Time:

1, 6 and 12 h
Result:

Significantly reduced the phosphorylation level of c-Myc protein Ser62 site.
Downregulated the expression of key enzymes in fatty acid synthesis (Acly, Acc1, Fasn).

Apoptosis Analysis^[7]

Cell Line:

HCT-116
Concentration:

50, 100, 200 μg/mL
Incubation Time:

48 h
Result:

Dose-dependently induced chromatin condensation in HCT-116 cells.
Dose-dependent lost mitochondrial membrane potential.

In Vivo

4-Methoxycinnamic acid ethyl ester (100-800 mg/kg, i.g., single dose) inhibited paw edema in a dose-dependent manner in rats^[4].
4-Methoxycinnamic acid ethyl ester (200-800 mg/kg, i.g., once daily for 7 days) inhibits the formation of chronic granuloma in a dose-dependent manner in rats^[2].
4-Methoxycinnamic acid ethyl ester (200-800 mg/kg, i.g., single dose) prolongs the tail-flick latency of rats in a dose-dependent manner, showing a significant analgesic effect^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Carrageenan-induced paw edema model established in male Sprague Dawely (SD) rats (150-200 g)^[1]
Dosage:

100, 200, 400 and 800 mg/kg
Administration:

Oral gavage (i.g.), single dose
Result:

Inhibited paw edema in a dose-dependent manner, with the minimum effective dose (MIC) being 100 mg/kg.
No toxic reactions were observed at 2000 mg/kg.

Animal Model:

Cotton pellet granuloma assay established in male Sprague Dawely (SD) rats (200-250 g)^[2]
Dosage:

200, 400, 800 mg/kg
Administration:

Oral gavage (i.g.), once daily for 7 days
Result:

Reached inhibition rate by 51.65% at 800 mg/kg.
Inhibited the production of key pro-inflammatory cytokines IL-1β and TNF-α.

Animal Model:

Tail flick assay established in male Sprague Dawely (SD) rats (200-250 g)^[2]
Dosage:

200, 400, 800 mg/kg
Administration:

Oral gavage (i.g.), single dose
Result:

Prolonged the tail-flick latency of rats in a dose-dependent manner

Chemical Information

CAS No. 1929-30-2
Appearance Solid
Molecular Weight 206.24
Formula C₁₂H₁₄O₃
Color Off-white to light yellow
SMILES

O=C(OCC)/C=C/C1=CC=C(OC)C=C1
Synonyms

Ethyl p-methoxycinnamate
Structure Classification
- Terpenoids
- Iridoids
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (484.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.8487 mL

24.2436 mL

48.4872 mL

5 mM

0.9697 mL

4.8487 mL

9.6974 mL

10 mM

0.4849 mL

2.4244 mL

4.8487 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (12.12 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Umar MI, et al. Bioactivity-Guided Isolation of Ethyl-p-methoxycinnamate, an Anti-inflammatory Constituent, from Kaempferia galanga L. Extracts. Molecules. 2012 Jul 23;17(7):8720-34. [Content Brief]

[2]. Umar MI, et al. Ethyl-p-methoxycinnamate isolated from Kaempferia galanga inhibits inflammation by suppressing interleukin-1, tumor necrosis factor-α, and angiogenesis by blocking endothelial functions. Clinics (Sao Paulo). 2014 Feb;69(2):134-44. [Content Brief]

[3]. Lakshmanan D, et al. Ethyl p-methoxycinnamate isolated from a traditional anti-tuberculosis medicinal herb inhibits drug resistant strains of Mycobacterium tuberculosis in vitro. Fitoterapia. 2011 Jun;82(4):757-61. [Content Brief]

[4]. Lallo S, et al. Ethyl P-Methoxycinnamate: An Active Anti-Metastasis Agent and Chemosensitizer Targeting NFKB from Kaempferia galanga for Melanoma Cells. Life (Basel). 2022 Mar 24;12(4):337. [Content Brief]

[5]. Tarasuk M, et al. Dual action effects of ethyl-p-methoxycinnamate against dengue virus infection and inflammation via NF-kB pathway suppression. Sci Rep. 2024 Apr 23;14(1):9322. [Content Brief]

[6]. Sasaki Y, et al. Ethyl p-methoxycinnamate inhibits tumor growth by suppressing fatty acid synthesis and depleting ATP. Sci Rep. 2025 May 2;15(1):15317. [Content Brief]

[7]. Umar MI, et al. Cytotoxic and Pro-Apoptotic Properties of Ethyl-p-Methoxycinnamate and Its Hydrophilic Derivative Potassium-p-Methoxycinnamate. Chemistry Africa. 2018 Jul 31;1(1-2):87-95.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.8487 mL	24.2436 mL	48.4872 mL	121.2180 mL
	5 mM	0.9697 mL	4.8487 mL	9.6974 mL	24.2436 mL
	10 mM	0.4849 mL	2.4244 mL	4.8487 mL	12.1218 mL
	15 mM	0.3232 mL	1.6162 mL	3.2325 mL	8.0812 mL
	20 mM	0.2424 mL	1.2122 mL	2.4244 mL	6.0609 mL
	25 mM	0.1939 mL	0.9697 mL	1.9395 mL	4.8487 mL
	30 mM	0.1616 mL	0.8081 mL	1.6162 mL	4.0406 mL
	40 mM	0.1212 mL	0.6061 mL	1.2122 mL	3.0304 mL
	50 mM	0.0970 mL	0.4849 mL	0.9697 mL	2.4244 mL
	60 mM	0.0808 mL	0.4041 mL	0.8081 mL	2.0203 mL
	80 mM	0.0606 mL	0.3030 mL	0.6061 mL	1.5152 mL
	100 mM	0.0485 mL	0.2424 mL	0.4849 mL	1.2122 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

4-Methoxycinnamic acid ethyl ester

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

NF-κB Signaling Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Antibacterial Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Glycolysis Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Anti-tuberculosis Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cysteine Targeted Covalent Library

Cysteine Targeted Covalent Fragment Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Cosmetic Ingredient Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

All COX Isoforms

All NF-κB Isoforms

All TNF Receptor Isoforms

All Interleukin Related Isoforms

All VEGFR Isoforms

All Caspase Isoforms

Biological Activity